Oncolytic Virotherapy

Global Oncolytic Virotherapy Market to Reach US$92.0 Million by 2030

The global market for Oncolytic Virotherapy estimated at US$27.5 Million in the year 2024, is expected to reach US$92.0 Million by 2030, growing at a CAGR of 22.3% over the analysis period 2024-2030. Genetically Engineered Oncolytic Virus, one of the segments analyzed in the report, is expected to record a 24.0% CAGR and reach US$65.5 Million by the end of the analysis period. Growth in the Oncolytic Wild Type Virus segment is estimated at 18.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.2 Million While China is Forecast to Grow at 21.0% CAGR

The Oncolytic Virotherapy market in the U.S. is estimated at US$7.2 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$14.0 Million by the year 2030 trailing a CAGR of 21.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 20.8% and 19.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.2% CAGR.

Global Oncolytic Virotherapy Market - Key Trends & Drivers Summarized

Why Is Oncolytic Virotherapy Emerging as a Distinct Modality in Cancer Treatment?

Oncolytic virotherapy is an innovative cancer treatment that uses genetically modified or naturally occurring viruses to selectively infect and destroy tumor cells while sparing healthy tissue. These viruses replicate within cancer cells, triggering direct cell lysis and stimulating systemic anti-tumor immune responses. Unlike traditional therapies, oncolytic viruses offer dual therapeutic action—cytotoxicity and immunomodulation—making them attractive for both solid tumors and hematologic malignancies.

This modality addresses key limitations of chemotherapy and targeted agents by penetrating the tumor microenvironment, inducing immunogenic cell death, and overcoming resistance mechanisms. Oncolytic viruses are being developed as monotherapies and in combination with immune checkpoint inhibitors, radiation, and CAR-T therapies. With increasing interest in immuno-oncology and the limitations of existing treatments for late-stage cancers, virotherapy is gaining attention for its potential to enhance durable responses in otherwise refractory cases.

How Are Technological Advances Accelerating Virotherapy Development?

Advancements in synthetic biology, genome editing, and viral engineering are significantly expanding the therapeutic potential of oncolytic virotherapy. Various viral platforms—including adenoviruses, herpes simplex virus (HSV), vaccinia, reovirus, and coxsackievirus—are being optimized for tumor selectivity, enhanced replication, and controlled immunogenicity. Genetic modifications allow insertion of transgenes that encode immune-stimulatory molecules such as GM-CSF, IL-12, or immune checkpoint inhibitors to augment local and systemic responses.

Vector engineering also enables improved viral targeting, reduced off-target toxicity, and evasion of host immune clearance. Controlled replication mechanisms and tumor-specific promoters are being used to restrict viral activity to cancerous tissues. Formulation improvements, such as nanoparticle encapsulation and intratumoral delivery systems, are enhancing bioavailability and therapeutic reach. These innovations are helping overcome early limitations related to viral spread, immune neutralization, and manufacturing scalability.

What Clinical and Regulatory Trends Are Advancing Market Adoption?

The clinical landscape for oncolytic virotherapy is rapidly evolving, with several candidates advancing through late-stage trials. The regulatory approval of talimogene laherparepvec (T-VEC) for melanoma marked a significant milestone, validating virotherapy as a viable cancer treatment. Ongoing clinical programs are evaluating virotherapies across indications such as glioblastoma, pancreatic cancer, bladder cancer, and triple-negative breast cancer. Trials increasingly focus on combination regimens with PD-1/PD-L1 inhibitors to enhance response rates and overcome immune resistance.

Regulatory agencies are showing growing openness to novel biological therapies, offering fast-track designations and orphan drug status to promising candidates. Encouragement for biomarker-driven development and companion diagnostics is shaping more targeted clinical trial designs. Collaborations between biotech firms, academic research centers, and large pharmaceutical companies are also accelerating development timelines and resource access. These trends are contributing to a more structured and supportive environment for market entry and expansion.

What Factors Are Driving Growth in the Oncolytic Virotherapy Market?

Growth in the oncolytic virotherapy market is driven by several factors. Rising incidence of cancers unresponsive to standard therapies is creating demand for novel treatment options with immune-activating potential. Advances in viral vector design and transgene delivery are improving safety, targeting accuracy, and efficacy. Increasing success of immuno-oncology therapies is promoting the development of virotherapy as a synergistic approach. Expanding clinical data and regulatory support are validating the therapeutic promise of oncolytic viruses. Strategic partnerships, R&D investment, and innovation in delivery methods are further enabling commercialization. Additionally, growing interest in personalized medicine is supporting development of tumor-specific and biomarker-guided virotherapies. These combined forces are positioning oncolytic virotherapy as a fast-evolving segment within the cancer therapeutics market.

SCOPE OF STUDY:

The report analyzes the Oncolytic Virotherapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Virus Type (Genetically Engineered Oncolytic Virus, Oncolytic Wild Type Virus); Application (Lung Cancer Application, Breast Cancer Application, Colorectal Cancer Application, Melanoma Application, Prostate Cancer Application, Head & Neck Cancer Application, Ovarian Cancer Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Cancer Research Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 48 Featured) -

• Amgen Inc.
• Astellas Pharma Inc.
• BioVex, Inc.
• DNAtrix Inc.
• Elicera Therapeutics AB
• Genelux Corporation
• Imugene Ltd
• Lokon Pharma AB
• Oncolys BioPharma
• Oncolytics Biotech Inc.
• Oncorus Inc.
• Pfizer Inc.
• Replimune Group Inc.
• SillaJen Inc.
• Sorrento Therapeutics Inc.
• Takara Bio Inc.
• Targovax ASA
• Transgene SA
• VCN Biosciences
• Vyriad Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more